Form 4: Gilead Executive Telman Reports Routine Stock Transactions

Gilead Sciences' EVP Deborah H. Telman reported the vesting of restricted stock units and subsequent share sales for tax obligations.

Summary

• Deborah H. Telman, Executive Vice President of Corporate Affairs & General Counsel at Gilead Sciences, Inc. (GILD), reported transactions on September 10, 2025.
• Acquired 1,315 shares of Common Stock through the vesting of Restricted Stock Units (RSUs).
• Disposed of 634 shares of Common Stock at a price of $115.25 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, beneficial ownership of Common Stock stands at 43,402 shares.
• The reporting person also holds 20,331 derivative securities in the form of Restricted Stock Units.
• Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
• The Restricted Stock Units have a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date, and the balance vesting 6.25% quarterly thereafter until fully vested.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions related to executive compensation, specifically the vesting of restricted stock units and the sale of shares for tax purposes. This is a standard event and does not indicate significant positive or negative operational news, but the executive's continued equity holdings align interests with shareholders.

Positives

• The acquisition of 1,315 shares through RSU vesting indicates the executive's continued alignment of interests with shareholders through equity ownership.
• The transactions are part of a standard executive compensation structure, reflecting the company's commitment to performance-based incentives.

Negatives

• The disposal of 634 shares, while for tax purposes, slightly reduces the executive's direct common stock holdings.

Future Outlook

The remaining 20,331 Restricted Stock Units held by the reporting person are subject to a four-year vesting schedule, with future share acquisitions expected as these units vest, starting with 25% on the first anniversary of the grant date and 6.25% quarterly thereafter.

Industry Context

Form 4 filings detailing executive stock transactions, particularly those related to the vesting of equity awards and subsequent tax-related sales, are routine in the pharmaceutical and biotechnology industries. This reflects common executive compensation practices designed to align management incentives with long-term shareholder value.

Comparison to Industry Standards

• Equity-based compensation, such as Restricted Stock Units (RSUs) with multi-year vesting schedules, is a standard practice for executive compensation across the pharmaceutical and biotechnology sectors, comparable to structures seen at companies like Amgen, Biogen, or Bristol Myers Squibb.
• The disposal of shares to cover tax withholding obligations upon the vesting of equity awards is a common and expected procedure for executives in publicly traded companies, consistent with practices observed across the S&P 500.

Stakeholder Impact

• Shareholders: The executive's continued equity ownership aligns their interests with those of shareholders. The reported transactions are routine and do not indicate a material change in company operations or strategy.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Continued vesting of the remaining 20,331 Restricted Stock Units according to the established four-year schedule.

Key Dates

Keywords

Gilead Sciences, GILD, Form 4, Insider Transaction, Deborah H. Telman, Restricted Stock Units, RSU, Stock Vesting, Executive Compensation